WO2003075955A1 - Procede permettant d'accroitre des reponses immunitaires par administration de l'adn de la nucleoproteine (np) de la grippe dans une immunisation adn - Google Patents

Procede permettant d'accroitre des reponses immunitaires par administration de l'adn de la nucleoproteine (np) de la grippe dans une immunisation adn Download PDF

Info

Publication number
WO2003075955A1
WO2003075955A1 PCT/KR2003/000471 KR0300471W WO03075955A1 WO 2003075955 A1 WO2003075955 A1 WO 2003075955A1 KR 0300471 W KR0300471 W KR 0300471W WO 03075955 A1 WO03075955 A1 WO 03075955A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
influenza
virus
vaccine
gene
Prior art date
Application number
PCT/KR2003/000471
Other languages
English (en)
Inventor
Young Chul Sung
You Suk Suh
Jae Ho Cho
Jun Chang
Hwa Sun Hahn
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Priority to AU2003212692A priority Critical patent/AU2003212692A1/en
Publication of WO2003075955A1 publication Critical patent/WO2003075955A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of influenza NP (nucleoprotein) DNA as an adjuvant for enhancing immune responses to a coimmunized DNA.
  • the present invention relates, in particular, to a method for enhancing immune responses by codelivering an influenza NP DNA and a DNA vaccine against an antigen, and a vaccine composition comprising said influenza NP DNA and said DNA vaccine for the antigen.
  • NP gene Ulmer JB, Science, 259:1745
  • HA Robot HL, Vaccine, 11:957
  • matrix Okuda K, Vaccine, 19:3681
  • neuraminidase Chon Z, Vaccine, 18:3214
  • Immunization with the DNA mixtures of genes of several antigens is required in some cases: (1) where the immune responses against several antigens are indispensable for obtaining the protective effect against one type of viral infection (Chen Z, Vaccine, 17:653; Bot A, Vaccine, 16:1675), (2) where for protection from a virus with a rapid mutation property, it is necessary to immunize with DNA encoding its various mutant antigens at the same time (Lu S., J Virol. 70:3978), and (3) where it is required to obtain simultaneously and simply the immune responses against more than two types of viruses.
  • Multivalent DNA vaccine technology for coimmunization with DNA encoding genes of several antigens has been used for DNA immunization against several viruses such as HIV (Amara RR, Science, 292:69), SIV (Lu S. J. Virol. 70:3978), HBV (Musacchiro A, BBRC, 282:442), etc.
  • viruses such as HIV (Amara RR, Science, 292:69), SIV (Lu S. J. Virol. 70:3978), HBV (Musacchiro A, BBRC, 282:442), etc.
  • influenza DNA immunization NP DNA + HA DNA immunization, NA DNA + HA DNA immunization and the like have also been tried and these coimmunizations were confirmed to exhibit a higher protective efficiency, as compared with immunization with DNA of one type antigen alone (Chen Z, Vaccine, 17:653; Bot A, Vaccine, 16:1675).
  • cytokine genes such as IL-2 (Lee et al, Vaccine, 17:473), GMCSF (Lee et al, J Virol. 72:8430; Cho et al, Vaccine, 17:1136) and IL-12 (Kim JJ et al, J Immunol. 158:816), and codelivery of a synchronic stimulating molecular gene such as CD40L (Gurunathan S et al., J. Immunol.
  • the inventors of the present invention found that, when administering a DNA vaccine together with an influenza NP gene DNA, the antibody response and CTL response to the DNA vaccine are enhanced and the secretion of IFN- ⁇ increases, as compared with administration of the DNA vaccine alone, such that the antibody immune response induced by the DNA vaccine can be enhanced.
  • the present invention was accomplished based upon the above novel fact.
  • An object of the present invention is to provide a method for enhancing an immune response by administering a DNA vaccine against an antigen (sometimes, referred to as "immune antigen") together with an influenza NP gene DNA, and a vaccine composition comprising said DNA vaccine against the immune antigen and said influenza NP gene DNA.
  • an antigen sometimes, referred to as "immune antigen”
  • the present invention provides the method for enhancing the immune response by administering the DNA vaccine against the immune antigen together with the influenza NP gene DNA. Furthermore, the present invention provides the vaccine composition comprising said DNA vaccine against the immune antigen and said influenza NP gene DNA.
  • the present invention provides use of said influenza NP gene DNA as an adjuvant to enhance an immune response.
  • the influenza NP gene DNA in the present invention is DNA having a nucleotide sequence for encoding a protein having more than 90% amino acid sequence homology to an influenza NP protein.
  • the full or partial region of said DNA is used for the present invention. More preferably, the full or partial region of DNA having the nucleotide sequence described in "Sequence No. 1" is used for the present invention.
  • the partial region of influenza NP gene is used, the same effect can be exhibited under the condition that said DNA has a nucleotide sequence for encoding the amino acid sequence which includes more than the N-terminal 50% or more than the C- terminal 50% of influenza NP protein,
  • the influenza NP gene DNA of the present invention is administered together with a DNA vaccine, preferably, with the influenza NP gene DNA inserted into an expression vector.
  • the expression vector for insertion of said influenza NP gene DNA thereinto is, preferably, a vector having the transcription promotor selected from a group consisting of CMV (cytomegalovirus) promotor, RSV (Rous sarcoma virus) promotor, ⁇ -actin promotor, SV40 (simian virus 40) promotor and muscle creatine kinase promotor, and the transcription terminator selected from a group consisting of SV40 poly(A) and BGH terminator; more preferably, an expression vector having the early promotor / enhancer sequence of cytomegalovirus and the adenovirus tripartite leader / intron sequence and containing the replication orgin and poly(A) sequence of SV40.
  • the inventors of the present invention created pTV-NP by inserting the influenza NP gene DNA, having the nucleotide sequence of Sequence No. 1 , into pTV 2 expression vector, and transformed Escherichia coli with said pTV-NP.
  • This transformant named as "XLl-blue/pTV-NP", was deposited in Gene Bank (located in Korea Research Institute of Bioscience and Biotechnology) under the accession No. KCTC 10193BP on February 27, 2002.
  • the DNA vaccine of the present invention is administered together with the influenza NP gene DNA, upon inoculation of the DNA vaccine against one or more immune antigens selected from a group consisting of influenza, varicella virus, diphtheria, tetanus, polio virus, malaria, herpes virus, HIV, papilloma virus, hepatitis B virus, hepatitis C virus, rotavirus, cholera, measles and tuberculosis.
  • This coimmunization enhances the antigen-specific antibody response and CTL (cytotoxic T lymthocytes) response and increases the secretion of IFN- ⁇ to enhance Th-1 (helper T cell) such that the immune response induced by the DNA vaccine is enhanced.
  • influenza NP gene DNA having the nucleotide sequence, described in Sequence No. 1 was inserted into pTV2 vector to prepare pTV-NP, and then the immune response induced by the influenza NP gene DNA was tested.
  • 'NP DNA' coimmunization with influenza HA DNA and influenza NP gene DNA
  • the antibody response specific to HA increases due to several effects caused by coimmunization.
  • Immunization with even a small amount of NP DNA can induce a strong antibody response and CTL response for a short time, which was first found by the inventors of the present invention and other researchers (Lee SW, Immunology 94:285).
  • the strong helper T cell response, induced by NP DNA immunization leads to activation or production of a factor, being capable for activating a nonspecific immune response such as cytokine secretion, whereby the immune response specific to HA (antibody, CD4 and CD8 responses) is enhanced.
  • NP DNA in the present invention can be understood to have the function of a genetic carrier, similar to HBV S gene, above.
  • immunization with HA DNA had no effect on the NP-specific immune response, which may be because a specific immune response induced by NP DNA is relatively stronger than the HA-specific immune response induced by HA DNA.
  • coimmunization with NP DNA enhances the antibody immune response induced by the other DNA vaccine, being simultaneously administered, while not enhancing the NP-specific antibody response induced by NP DNA per se.
  • NP DNA can be used as a genetic immune response adjuvant for a DNA vaccine against influenza, HIV, hepatitis C virus, measles, tuberculosis, etc.
  • coimmunized viruses, which NP DNA can be applied as an immune response adjuvant to are not limited to the above ones but include the ones with properties similar to the above viruses.
  • the above result shows that coimmunization with a DNA vaccine and NP DNA increases Th-1 response as well as antibody response and CTL response.
  • NP DNA of the present invention can also be used as an adjuvant for enhancing the immune response to other types of coimmunized antigens, e.g., OVA (ovalbumin), in addition to HA, HIV env and HCT E2, simultaneous administration of OVA DNA and NP DNA increased the amount of OVA-specific IFN- ⁇ producing T-cells, as compared with the case of administering OVA DNA alone (refer to FIG. 5).
  • OVA ovalbuproliferative fibroblasts
  • NP DNA The adjuvant effect of NP DNA on the immune response can also be directly observed in vivo; i.e., CD4 or CD8 T cellular response, induced by other antigens such as HA, Env, E2 etc., administered together with NP DNA, in particular, the rate of cell division was observed to increase.
  • OT-II cell division which was not observed upon administration of OVA DNA alone, could be remarkably induced when OVA DNA was administered together with NP DNA (refer to FIG. 6).
  • OT-II cells need about 100 times more antigen than do OT-I cells so as to be induced to divide in vitro or in vivo (Ming L et al., J Immunol.
  • NP DNA immunization increases the specific immune response to a coimmunized DNA
  • immunization with the mixture of HIV env DNA and HCV E2 DNA may decrease the CTL response induced by each DNA.
  • the E2-specific CTL response showed lysis values of 10.6% and 13.6%, respectively, in two separate analyses, upon coimmunization with env DNA and E2 DNA, but 45.1% and 33.4% upon immunization with E2 DNA alone.
  • the env-specific CTL response was lower upon coimmunization with env DNA and E2 DNA (4.1%, 0.2%) than upon immunization with env DNA (26.7%, 18.3%) alone. Accordingly, upon coimmunization with the mixture of two types of antigen DNAs, increase of the immune response specific to one type of antigen depends upon the kind of antigen, and occurs only upon using the gene of a specific antigen, such as NP DNA.
  • the NP DNA + HA DNA immunization increases the initial survival rate and mean body weight upon infection with the lethal dose of viruses, as compared with NDNA immunization or HA DNA immunization alone (refer to FIG. 8).
  • FIG. 8 shows that when mice were immunized with the mixture of NP DNA (PPJ8) vaccine and HA DNA (WSN) vaccine and then challenged with influenza virus strain WSN, the survival rate of mice increased, as compared with immunization with one of HA DNA and NP DNA.
  • the above report also showed that, upon challenging mice in the same group with PR/8 virus, the survival rate of mice did not increase.
  • NP DNA as an adjuvant for enhancing an immune response to a coimmunized DNA in the present invention will assist in development of influenza vaccines, and also assist research on immune response adjuvants for AIDS and Hepatitis vaccine and research for efficiency enhancement of a vaccine comprising two or more types of DNAs.
  • the system used in the present invention can be applied to the research models of immune interference or enhancement in DNA immunization with multiple- components.
  • the present invention provides a vaccine composition comprising an influenza NP gene DNA and a DNA vaccine against an immune antigen.
  • the Influenza NP gene DNA in the present invention is DNA having a nucleotide sequence for encoding a protein having more than 90% amino acid sequence homology to the influenza NP protein.
  • the full region of said DNA or a partial region having more than 50% of the full region can be used for the vaccine composition of the present invention. More preferably, the full region of DNA having the nucleotide sequence described in "Sequence No. 1" or a partial region having more than 50% thereof can be used for the vaccine composition of the present invention.
  • influenza NP gene DNA is preferably used in a form inserted into an expression vector.
  • the expression vector for insertion of said influenza NP gene DNA thereinto is, preferably, a vector having the transcription promotor selected from a group consisting of CMV (cytomegalovirus) promotor, RSV (Rous sarcoma virus) promotor, ⁇ -actin promotor, SV40 (simian virus 40) promotor and muscle creatine kinase promotor, and the transcription terminator selected from a group consisting of SV40 poly(A) and BGH terminator; more preferably, a vector having the early promotor/enhancer sequence of cytomegalovirus and the adenovirus tripartite leader/intron sequence, and containing the replication orgin and poly(A) sequence of SV40; especially preferably, pTV-NP with the influenza NP gene DNA, having the nucleotide sequence of Sequence No. 1, inserted into pTV 2 expression vector.
  • CMV cytomegalo
  • the DNA vaccine in the vaccine composition of the present invention is a DNA vaccine against one or more immune antigens selected from a group consisting of influenza, varicella virus, diphtheria, tetanus, polio virus, malaria, herpes virus, HIV, papilloma virus, hepatitis B virus, hepatitis C virus, rotavirus, cholera, measles and tuberculosis; however, said DNA vaccine is not limited to the above ones.
  • the formulation process is simple for simultaneously obtaining immune responses against several antigens; i.e., the immune responses against several antigens can be obtained by simply mixing DNA vectors having the gene of each antigen.
  • the vaccine composition of the present invention contains 1 - 99% by weight, preferably, 25 - 60% by weight of said influenza NP gene DNA on the basis of the total weight of composition; however, it is not limited to this range and can be changed, depending upon the type of DNA vaccine, and a patient's condition.
  • soluble excipients can be contained into the vaccine composition of the present invention, in addition to said NP DNA and DNA vaccine, which examples of these excipients include carbohydrate, amino acid, fatty acid, inorganic salt, surfactant, polyethylene glycol, mixtures of these, etc.
  • carbohydrate include soluble sugars such as hydropropyl cellulose, carboxymethyl cellulose, sodium carboxyl cellulose, hyaluronic acid, chitosan, alginate, glucose, xylose, galactose, fructose, maltose, saccharose, dextran, chondroitin sulfate, etc.
  • Representative examples of said protein include albumin, gelatin, etc.
  • Representative examples of said amino acid include glycine, alanine, glutamic acid, arginine, lysine, and their salts.
  • the vaccine composition of the present invention may be filled with ones selected from a group consisting distilled water, saline solution and PBS (phosphate buffered saline) with influenza NP gene DNA and DNA vaccine.
  • the vaccine composition of the present invention follows general administration and formulation methods of DNA vaccine (Wolff et al., Science, 1990, 247:1465).
  • DNA vaccine can be delivered to exodermis by the direct injection, particle impact or electroporation method, or be delivered to exodermis by the complex and/or repeated administration method.
  • DNA vaccine can also be administered by coating DNA onto a gold bead and then delivering the gold bead into cells using a gene gun (Porgador et al., The Journal of Experimental Medicine, 1998, 188:1075).
  • the vaccine composition of the present invention can be formulated as an oral drug or non-oral drug by general methods and then administered via an oral or non-oral route.
  • diluents or excipients such as filler, extender, coupler, wetting agent, disintegrant, surfactant and the like are generally used.
  • Solid drugs for oral administration include tablet, pill, powder, granule, capsule, etc. These solid drugs can be prepared by mixing more than one excipient such as calcium carbonate, sucrose or lactose, gelatin, etc.
  • lubricants such as magnesium stylate talc can also be used.
  • Liquid drugs for oral administration include suspension, solution, emulsion, syrup, etc., and can contain several general excipients such as wetting agent, sweet agent, aromatic agent, preservative in addition to diluents such as water or liquid paraffin.
  • Drugs for non-oral administration include sterile solution, non- soluble solution, suspension, emulsion, lyophilized drug, suppository, etc.
  • used can be vegetable oil such as propylene glycol, polyethylene glycol, olive oil, etc. and injectable ester such as ethyl olerate.
  • compositions of the present invention can be formulated to liquid or dry powder capable of being administered in the form of aerosol spray.
  • the administration amount and number of the vaccine composition of the present invention can be determined by the proper administration amount and number, known for an antigen as used, and can be changed depending upon body weight, age, sex, health condition, food, administration time, administration method, excretion rate, extent of illness, etc.
  • the effective amount of Influenza NP gene DNA, contained in the composition of the present invention is 10 ⁇ g - 10 mg/kg by body weight and, preferably, 100 ⁇ g - 5 mg/kg by body weight. Furthermore, the vaccine composition of the present invention is not toxic and thus very safe as a DNA vaccine.
  • FIG. 1(A) is a genetic map of vector, illustrating regions where NP gene DNA (NP DNA: 1.5 kb) and HA DNA (1.7 kb) are inserted into ⁇ TV2 vector
  • FIG. 1(B) is photographs taken by the radioimmunoprecipitation method, when having expressed pTV-NP and pTV-HA in COS-7 cells.
  • FIG. 2(A) is graphs of the antibody response analyzed by conducting ELISA with HA-specific antibody or NP-specific antibody, when having immunized mice with NP DNA, HA DNA, or NP DNA + HP DNA
  • FIG. 2(B) is graphs of HA-specific or NP-specific CTL response analyzed when having immunized mice with NP DNA, HA DNA, or NP DNA + HA DNA.
  • FIGS. 3(A) and 3(B) are graphs of the antibody response analyzed by conducting ELISA with HIV-specific antibody, E2-specific antibody, or NP-specific antibody, when having coimmunized mice with env or E2 DNA and NP DNA
  • FIGS. 3(C) and 3(D) are graphs of env-specific CTL, E2-specific CTL or NP-specific CTL response analyzed when having coimmunized mice with env or E2 DNA and NP DNA.
  • FIG. 4 is a graph of the IFN- ⁇ concentration, secreted from HA-stimulated lymphocyte, analyzed by ELISA, when having immunized mice with HA DNA, NP DNA, HA DNA + NP DNA, or DNA.
  • FIG. 5 is graphs of the number of IFN- ⁇ secreting cells, by NP peptide, OVA257-264 peptide, or OVA323-339 peptide, analyzed by ELISPOT, when having immunized mice with NP DNA.
  • FIG. 6 is photographs of showing proliferation of CFSE-labeled OT-I cells, analyzed by a laticiferous cell analyzer, when having immunized mice with NP DNA + OVA DNA, OVA DNA, or NP DNA.
  • FIG. 7 is photographs of showing proliferation of CFSE-labeled OT-II cells, analyzed by the laticiferous cell analyzer, when having coimmunized mice with NP DNA + OVA DNA, OVA DNA, or NP DNA.
  • FIG. 8 is graphs of illustrating the change of survival rate (A) and mean body weight (B), when having challenged mice with the lethal influenza dose after immunization with NP DNA + HA DNA, NP DNA, HA DNA, or control DNA.
  • the inventors of the present invention obtained the desired genes from viruses to prepare a DNA vaccine. Specifically, MDCK cells were infected with Influenza
  • the pTV vector has the early promotor/enhancer sequence of Cytomegalovirus and the adenovirus tripartite leader/intron sequence and contains the replication orgin and polyA sequence of SV40.
  • pTX GE (Lee AH et al., Vaccine, 17:473) containing the HIV env gene was cleaved by MM and Hpal, and inserted into pTV2 vector to prepare pTV-GE.
  • pTV-gDs-E2t (Lee SW, J. Virol. 72:8430) was used without any modification.
  • Chicken OVA (ovalbumin) cDNA from Tc-OVA vector was amplified by PCR and inserted into pTV2 vector to prepare pTV-OVA.
  • Each DNA vaccine was grown in E. coli and then purified using endotoxin-free kit (QIAGEN).
  • the DNA vaccine as prepared above was confirmed by transient transfection assay. Specifically, 3 x 10 5 COS-7 cells were transfected with 10 ⁇ g of pTV-NP, pTV- HA or pTV-OVA by the calcium phosphate method. Forty-eight hours after transfection, the cells were labeled with 32S-Met for 12 hours and harvested. The expression of NP and HA proteins was confirmed using anti-Flu (PR/8/34) mouse serum by the radioimmunoprecipitation (RIP) method (refer to FIG. IB) and OVA protein was confirmed using the anti-OVA (Sigma). The expression of pTV-OVA and pTV-GE was confirmed by Western Blot Analysis (Lee AH et al., Vaccine, 17:473)
  • EXAMPLE 2 Increase of HA-specific antigen and CTL responses by coimmunization with NP DNA
  • mice To analyze the antigen-specific response and CTL response upon coimmunization by simultaneous administration of HA DNA vaccine and NP DNA vaccine, as prepared in EXAMPLE 1, the inventors of the present invention immunized mice (BALB/c) with one of the mixtures of NP DNA + HA DNA, NP DNA + vector, or HA DNA + (empty) vector two times at 4-week intervals, then took blood from the mice in each group at 4 weeks after the final immunization to measure the anti-NP response and anti-HA response.
  • mice of BALB/c or C57BL/6 character 4 to 5-week-old when purchased from B & K Universal Inc.
  • pTV-NP 50 ⁇ g
  • pTV-HA 50 ⁇ g
  • pTV-gDs-E2t 50 ⁇ g
  • pTV-GE 50 ⁇ g
  • ELISA for detection of the anti-NP antibody response and anti-HA antibody response was conducted by the known method (Sin JI, Vaccine, 15:1827).
  • HA and NP proteins were partially purified from an Influenza bulk vaccine solution (LG chemical Co. Ltd.) using Con-A Cephalos (Pharmacia) column according to the manufacturer's instruction, then each protein solution was separated by SDS-PAGE. Gels corresponding to NP and HA protein bands were cut out and each protein was obtained by the electroelution method.
  • the purified NP protein and HA protein were diluted in PBS to 2 ⁇ g/ml, then 50 ⁇ l of the resulting protein solution was coated on ELISA plates for analysis.
  • mice in each group were maintained in a CTL analysis culture medium (RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 50 ⁇ M b-mercaptoethanol, and lOU/ml recombinant murine IL-2).
  • CTL analysis culture medium RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 50 ⁇ M b-mercaptoethanol, and lOU/ml recombinant murine IL-2).
  • NP peptide as described in Sequence No. 3
  • HA peptide as described in Sequence No. 4
  • cells were adjusted to 7 ⁇ M, then stimulated at 37°C in a CO 2 incubator for 6 days.
  • P815(H2d) target cells were pulsed with 5 ⁇ M of NP or HA peptide, followed by labeling with 51Cr, then reacted with the stimulated effector cell to measure cytotoxicity.
  • the coimmunization with NP DNA increases the antibody immune response induced by another DNA vaccine, which is administered together with NP DNA, without changing the NP-specific antibody response induced by NP ON A per se.
  • EXAMPLE 3 Analysis of effect of NP DNA on antibody response and CTL response to other viral antigens
  • the inventors of the present invention immunized Balb/c mice with HIV env DNA (pTV-GE) or HCV E2 DNA (pTV-gDs-E2t) and NP DNA 2 times at 4-week intervals to measure the NP-specific antibody response and CTL response, the env-specific antibody response and CTL response, and the E2-specific antibody response and CTL response, respectively.
  • mice immunization of mice was conducted in the same manner as EXAMPLE 2, and for administration of HA DNA, env DNA, E2 DNA or NP DNA, the mixture of 50 ⁇ g of each DNA vaccine (pTV-HA, pTV-GE, pTV-gDs-E2t) and 50 ⁇ g of vector (pTV) was used.
  • the splenocytes of non-immunized BALB/c mice were infected with a recombinant vaccine virus (rVV-env, NIH), expressing HIV env, to prepare stimulator cells and the stimulator cells were cultivated for 6 days together with the splenocytes of immunized mice.
  • rVV-env, NIH recombinant vaccine virus
  • the NP-specific antibody response to NP DNA + vector immunization did not have any difference from those to NP DNA + E2 DNA immunization and NP DNA + HIV env DNA immunization (refer to FIGS. 3A and 3B).
  • the HIV- 1 -specific antibody response was increased by coimmunization with NP DNA and, particularly, formation of the E2-specific antibody by E2 DNA + NP DNA immunization was greatly increased, showing a significant difference from the HIV- 1 -specific antibody response and E2-specific antibody formation in the E2 DNA + vector group (p ⁇ 0.05).
  • NP CTL response induced by NP DNA + vector immunization did not have any difference from those induced by NP DNA + E2 DNA immunization and NP DNA + HIV env DNA immunization.
  • communization with HIV env DNA or HCV E2 DNA and NP DNA increased the env-specific CTL response (from 19% to 51% lysis) or E2-specific CTL response (from 33% to 48% lysis), as compared with the cases of not using NP DNA (refer to FIGS. 3C and 3D).
  • NP DNA can also be used as immune response adjuvants for DNA vaccines against other types of viruses, such as HIV and HCV, as well as influenza vaccine.
  • EXAMPLE 4 Enhancement of IFN- ⁇ secretion from HA-stimulated lymphocytes of mice immunized with NP DNA + HA DNA
  • the inventors of the present invention stimulated the splenocytes of mice with HA protein or NP protein at 4 weeks after the final immunization to measure the concentration of IFN- ⁇ .
  • splenocytes isolated from the DNA-immunized mice were maintained in an analysis culture medium (RPMI 1640 supplemented with 10% FBS, 2 raM L-glutamine, 50 ⁇ M b-mercaptoethanol). 2 x 10 5 lymphocytes per well were put on 96-well round-bottomed plates, then stimulated at 37°C in CO 2 incubator by NP protein or HA protein which was added to the final concentration of 5 ⁇ g/ml. After 4 days, the concentration of IFN- ⁇ in the supernatant was measured using a kit (murine IFN- ⁇ ELISA kit; Pharmingen).
  • EXAMPLE 5 Analysis of OVA-specific IFN- ⁇ producing T cells by coimmunization with NP DNA + OVA DNA
  • OVA DNA was injected into C57BL/6 mice and, after 4 weeks, quantitative IFN- ELISPOT analysis was performed using I-Ab-restricted OVA peptide, H-2b-restricted OVA, or NP peptide.
  • pTV-NP and 50 ⁇ g of pTV-OVA were dissolved in 100 ⁇ l of PBS and the resulting solution was intramuscularly injected one time into the tibialis muscles in both legs of C57BL/6 mice by 50 ⁇ l.
  • the mixture of 50 ⁇ g of each DNA vaccine and 50 ⁇ g of empty vector (pTV2) was used in the same manner as the above.
  • the plates were washed 5 times with PBS (0.05% Tween 20) and treated with 2.5 ⁇ g/ml of biotin-conjugated anti-IFN detection Ab (BD Pharmingen) at RT (room temperature) for 2 hours, then washed 6 times with PBST. Streptavidin-conjugated alkaline phosphatase, as having been diluted to 1/2,000 with PBST, was treated at RT for 1 hour. Thereafter, a BCIP/NBT was added into the plates to react at RT for about 15 minutes. When blue spots were observed after several hours, the reaction was terminated with excess water. After the plates were dried at RT, the number of spots was counted using the optical microscope.
  • PBS 0.05% Tween 20
  • biotin-conjugated anti-IFN detection Ab BD Pharmingen
  • the NP DNA + OVA DNA injection group showed about a 3 - 4 times higher frequency of the I-Ab-restricted OVA NP peptide-specific IFN- ⁇ producing T cells than did the OVA DNA injection group (refer to FIG. 5C).
  • specific IFN- ⁇ producing T cells were rarely observed in the OVA DNA injection group and, in use of OVA peptide, they were rarely observed in the NP DNA injection group, which suggests that the above response is an antigen response specific to an injected DNA.
  • EXAMPLE 6 Analysis of CD8 or CD4 T cell proliferation response by NP DNA + OVA DNA
  • NP DNA affects CD8 or CD4 T cell proliferation in response to other co-injected antigens
  • the inventors of the present invention used respectively OT-I and OT-II cells, as CD8 and CD4 T cells specific to OVA, to analyze CD8 or CD4 T cell proliferation response.
  • TCR T Cell Receptor
  • OT-I or OT-II mice were used that were restricted to H-2b or I-Ab and specific to OVA (ovalbumin) epitope 257-264 or 323-339 region.
  • Single cell suspension was obtained from the lymph nodes of 6-week-old OT-I (or OT-II) mice, and treated with anti-HSA (Jl ld), anti-B220, anti-MHC class II, and anti-CD4 (or anti-CD8) single antibodies at 4°C for 30 minutes, then treated with a rabbit complement at 37°C for 45 minutes to obtain OT-I (or OT-II) cells at a purify of more than 95%.
  • anti-HSA Jl ld
  • anti-B220 anti-MHC class II
  • anti-CD4 anti-CD8
  • the separated OT- I (or OT-II) cells were diluted with PBS to a concentration of 2 x 10 7 cells/ml, and treated with 5 uM of CFSE (Carboxyfluorescein diacetate succinimidyl ester) at 37°C for 10 minutes so as to trace the cell division in vivo, thereby obtaining CFSE-labeled OT-I (or OT-II) cells.
  • CFSE Carboxyfluorescein diacetate succinimidyl ester
  • the 2 x 10 6 cells were labeled with CFSE fluorescent material and then injected into the blood vessel of 6 to 7-week-old female C57BL/6 mice.
  • NP DNA + OVA DNA, OVA DNA, or NP DNA was intramuscularly injected into the mice and, after 9 days, the lymph node drainage of each mouse was separated to analyze whether the cell division of the CFSE-labeled OT-I or OT-II cell occurred using a lacticiferous cell flow cytometry.
  • the lymph nodes of popliteal and inguinal were separated from the OVA DNA-injected mice to obtain single cell suspension.
  • the single cell suspension was treated with PerCP-conjugated anti-CD4 or CD8 mAb and PE-conjugated V2 mAb at 4°C for 15 minutes, then 50,000 - 100,000 cells were collected using FACScalibur (BD science). The analysis of cell division was performed using the CellQuest software.
  • OT-I and OT-II cell divisions were not observed (refer to FIGS. 6C and 7C), which means that the OT-I and OT-II cell divisions are an OVA antigen-specific response induced by OVA DNA.
  • NP DNA has an effect on CD8 or CD4 T cell response induced by other coimmunized DNA (HA, env, E2 or OVA), injected together with NP DNA, particularly, on the rate/induction of cell division.
  • coimmunized DNA HA, env, E2 or OVA
  • EXAMPLE 7 Increase of the initial survival rate after lethal influenza challenge
  • mice in each group were anesthetized with an avertin solution and infected with 50 LD 5 o of influenza A/Jap/57 via the intranasal route.
  • the body weight and survival of mice in each group were monitored at a selected date.
  • the mean weight of mice in each group was calculated by fixing the weight of surviving mice and the weight of dead mice by influenza infection as 0 value and then comparing the weight of mice before infection therewith. Survival and weight change of each mouse were monitored and observed until 20 days after infection.
  • the NP DNA + HA DNA-immunized mice group exhibited a survival rate of 42%, which is similar to or rather less than those of NP DNA + vector-immunized and HA DNA + vector-immunized mice groups, 50% and 45%, respectively (p > 0.2).
  • the survival rate of NP DNA + HA DNA-immunized mice group was higher than those of NP DNA + vector-immunized and HA DNA + vector-immunized mice group (refer to FIG. 8A).
  • the mean body weight of NP DNA + HA DNA- immunized mice group was also higher than those of any other groups (refer to FIG. 8B).
  • an influenza NP gene DNA is used as an adjuvant for a DNA vaccine to enhance the immune response of the DNA vaccine. Accordingly, this method can be used for effective prevention against or treatment of influenza, AIDS, hepatitis B, hepatitis C, cancer, tuberculosis, malaria, etc. and provide the information regarding the development of influenza vaccines. Furthermore, this method can help research into immune response adjuvants of AIDS and hepatitis, and research for effect enhancement of a vaccine comprising more than two DNA components. In addition, the system used in the present invention can be applied to the research models for immune interference or enhancement in DNA immunizations with multiple-components.
  • microorganism identified under 1 above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on
  • Na e Korean Collection for Type Cultures Signature(s) of person. s> having the power to represent the International Depositary Authority of authorized official. s>:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de l'ADN de la nucléoprotéine (NP) de la grippe comme adjuvant permettant d'accroître des réponses immunitaires dans un vaccin ADN, notamment un procédé permettant d'accroître des réponses immunitaires par administration simultanée de l'ADN de la NP de la grippe et d'un vaccin ADN contre un antigène immun, ainsi qu'une composition de vaccin renfermant l'ADN de la NP de la grippe et le vaccin ADN contre l'antigène immun. Selon le procédé selon l'invention, l'ADN du gène de la NP de la grippe est utilisé comme adjuvant pour un vaccin ADN, aux fins d'accroissement de la réponse immunitaire du vaccin ADN, afin qu'il puisse être utilisé pour une prévention/traitement efficace contre la grippe, le sida, l'hépatite B, l'hépatite C, le cancer, la tuberculose, la malaria, etc. et pour contribuer au développement de vaccins contre la grippe.
PCT/KR2003/000471 2002-03-13 2003-03-11 Procede permettant d'accroitre des reponses immunitaires par administration de l'adn de la nucleoproteine (np) de la grippe dans une immunisation adn WO2003075955A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003212692A AU2003212692A1 (en) 2002-03-13 2003-03-11 Method for enhancing immune responses by codelivering influenza np dna in dna immunization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0013574 2002-03-13
KR1020020013574A KR100600988B1 (ko) 2002-03-13 2002-03-13 Ｄｎａ 면역화에서 인플루엔자 ｎｐ 유전자 ｄｎａ를 함께투여하여 면역반응을 증가시키는 방법

Publications (1)

Publication Number Publication Date
WO2003075955A1 true WO2003075955A1 (fr) 2003-09-18

Family

ID=27800675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/000471 WO2003075955A1 (fr) 2002-03-13 2003-03-11 Procede permettant d'accroitre des reponses immunitaires par administration de l'adn de la nucleoproteine (np) de la grippe dans une immunisation adn

Country Status (3)

Country Link
KR (1) KR100600988B1 (fr)
AU (1) AU2003212692A1 (fr)
WO (1) WO2003075955A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1851238A2 (fr) * 2005-02-24 2007-11-07 University of Massachusetts Acides nucleiques d'influenza, polypeptides et leurs utilisations
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
EP2396033A2 (fr) * 2009-02-12 2011-12-21 MedImmune, LLC Hémagglutinine du virus de la grippe et variants de la neuraminidase
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8765136B2 (en) 2004-05-25 2014-07-01 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9028838B2 (en) 2006-08-09 2015-05-12 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016619A1 (fr) * 1991-03-19 1992-10-01 Us Army Expression dans le baculovirus d'antigenes de la nucleoproteine du virus grippal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
ES2113786B1 (es) 1994-07-05 1999-01-01 Subidor S A Embarcacion sumergible.
KR20000021490A (ko) * 1998-09-29 2000-04-25 정명식 독감 바이러스에 대한 디엔에이 백신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016619A1 (fr) * 1991-03-19 1992-10-01 Us Army Expression dans le baculovirus d'antigenes de la nucleoproteine du virus grippal

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIKO IWASAKI ET AL.: "Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines", THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 10, 1997, pages 4591 - 4601, XP002035095 *
LAWRENCES S.D. ANTHONY ET AL.: "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule", VACCINE, vol. 17, 1999, pages 373 - 383 *
SUDHIRDAS K. PRAYAGA ET AL.: "Manipulation of HIV-1 gp120-specfic immune responses elicited via gene gun-based DNA immunization", VACCINE, vol. 15, 1997, pages 1349 - 1352 *
WHIVER JOHN W. ET AL.: "Humoral and cellular immunities elicited by DNA vaccines: Application to the human immunodeficiency virus and influenza", ADVANCED DRUG DELIVERY REVIEWS, 1996, pages 19 - 31 *

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9752184B2 (en) 2001-03-02 2017-09-05 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8815513B2 (en) 2001-03-02 2014-08-26 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents in epidemiological and forensic investigations
US8265878B2 (en) 2001-03-02 2012-09-11 Ibis Bioscience, Inc. Method for rapid detection and identification of bioagents
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US9416424B2 (en) 2001-03-02 2016-08-16 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8802372B2 (en) 2001-03-02 2014-08-12 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8380442B2 (en) 2001-06-26 2013-02-19 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8921047B2 (en) 2001-06-26 2014-12-30 Ibis Biosciences, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US9725771B2 (en) 2002-12-06 2017-08-08 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8476415B2 (en) 2003-05-13 2013-07-02 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8013142B2 (en) 2003-09-11 2011-09-06 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US9447462B2 (en) 2004-02-18 2016-09-20 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US9449802B2 (en) 2004-05-24 2016-09-20 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8987660B2 (en) 2004-05-24 2015-03-24 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US8765136B2 (en) 2004-05-25 2014-07-01 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
EP1851238A2 (fr) * 2005-02-24 2007-11-07 University of Massachusetts Acides nucleiques d'influenza, polypeptides et leurs utilisations
US7566454B2 (en) 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
EP1851238A4 (fr) * 2005-02-24 2008-12-31 Univ Massachusetts Acides nucleiques d'influenza, polypeptides et leurs utilisations
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8551738B2 (en) 2005-07-21 2013-10-08 Ibis Biosciences, Inc. Systems and methods for rapid identification of nucleic acid variants
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US9028838B2 (en) 2006-08-09 2015-05-12 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8252599B2 (en) 2008-09-16 2012-08-28 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US9023655B2 (en) 2008-09-16 2015-05-05 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8609430B2 (en) 2008-09-16 2013-12-17 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9027730B2 (en) 2008-09-16 2015-05-12 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
RU2535970C2 (ru) * 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
US9165740B2 (en) 2009-02-12 2015-10-20 Ibis Biosciences, Inc. Ionization probe assemblies
US8796617B2 (en) 2009-02-12 2014-08-05 Ibis Biosciences, Inc. Ionization probe assemblies
EP2396033A4 (fr) * 2009-02-12 2013-10-23 Medimmune Llc Hémagglutinine du virus de la grippe et variants de la neuraminidase
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US9119812B2 (en) 2009-02-12 2015-09-01 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2396033A2 (fr) * 2009-02-12 2011-12-21 MedImmune, LLC Hémagglutinine du virus de la grippe et variants de la neuraminidase
AU2010213966B2 (en) * 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification

Also Published As

Publication number Publication date
KR20030073827A (ko) 2003-09-19
KR100600988B1 (ko) 2006-07-13
AU2003212692A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
WO2003075955A1 (fr) Procede permettant d'accroitre des reponses immunitaires par administration de l'adn de la nucleoproteine (np) de la grippe dans une immunisation adn
JP6195943B2 (ja) インフルエンザウイルスの複数のサブタイプに対する新規ワクチン
Sin et al. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene
Okada et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens.
JP4580410B2 (ja) 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法
Davis et al. DNA vaccines for viral diseases
JP2002508333A (ja) ワクチン
WO2021259206A1 (fr) Vaccin à adn pour le virus sars-cov-2 et son utilisation
US9381237B2 (en) Neutralizing immunogen (NimIV) of rhinovirus and its uses for vaccine applications
TW202039587A (zh) 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
Larijani et al. HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c
US20110129489A1 (en) Methods for generating an immune response using dna and a viral vector
Zuercher Upper respiratory tract immunity
JP2007508319A (ja) 方法
JP2021529538A (ja) 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス感染疾患の予防または治療用ワクチン組成物
KR100773390B1 (ko) 단순 포진 바이러스 백신 키트
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
EP1029549B1 (fr) Formulation d'acides nucleiques et acemannane
KR100597699B1 (ko) 면역원성이 증강된 ｄｎａ 백신 조성물
Neeli et al. Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
Liu et al. Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development
KR20170081646A (ko) 단순 포진 바이러스 유형 2(ｈｓｖ-2)에 대한 면역 반응을 유도하기 위한 치료 조성물 및 방법
WO1997028265A9 (fr) Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn
WO1997028265A1 (fr) Immunisation contre la rougeole par inoculation d'unites de transcription de l'adn
Shata et al. M Cell DNA Vaccination for CTL Immunity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP